Biomarker for efficient prediction and monitoring of tumor necrosis factor alpha in inflammation inhibition therapies
A German research institution has generated positive data on the use of interleukin-22 binding protein as biomarker for prediction and monitoring of the individual efficacy of anti-TNF-alpha treatments of Inflammatory Bowel Disease and other chronic inflammatory conditions. Sought are SMEs and MNEs of any size, which are involved in the development of such treatments, especially for optimization of anti-TNF-alpha therapy for licensing, transfer of rights, knowledge transfer, or R&D cooperation.
Sought are industrial partners of any size, both SMEs or MNEs, which are preferably involved in the treatment of Inflammatory Bowel Disease, optimization of anti-TNF-alpha therapy, and personalized medicine in general. Partners are sought for licensing, transfer of rights (pending patent), knowledge transfer, or R&D collaborations to test and refine the technology in commercially relevant projects. In focus of a possible collaboration could be the development of a market-ready diagnostic assay, or the support of prospective studies with larger groups of patients.
The pathogenesis of Inflammatory Bowel Disease (IBD) remains still unclear, yet it has been closely related to the inflammatory response. Current therapies target tumor necrosis factor alpha (TNF-alpha) to inhibit its inflammatory effects. The success of the therapy is monitored through observation of clinical symptoms and TNF-alpha antibodies level. This yields a limited amount of information, since the effects of the treatment are only detectable with the development of the patient’s wellbeing, hence in only ~ 50 % of the cases TNF-alpha-based treatments of IBD have the expected therapeutic effect. This inefficient monitoring entails remarkable disadvantages for the patient and health system, due to the side effects and high costs associated to TNF-alpha-blockers treatment. A German research group has generated positive data on the novel use of interleukin-22 binding protein (IL-22BP) as biomarker for the prediction and monitoring of the efficacy of anti-TNF-alpha treatments, allowing its consistent use. IL-22BP regulates the function of the free interleukin, and its downregulation apparently has a positive effect on the therapy. Therefore, monitoring IL-22BP could be used to predict therapy effectiveness and for measuring the course of the disease in treated patients. This would allow an early adaption or optimization of therapy conditions to the patient in a usually lifelong treatment thereby reducing costs and increasing wellbeing. The positive results generated so far are being currently validated in the frame of a prospective study. Partners could be enterprises of any size, both SMEs or MNEs, which are preferably active in the fields of Inflammatory Bowel Disease treatment, optimization of anti-TNF-alpha therapy, and personalized medicine. They could benefit from a transfer of rights of the existing IP (patent pending), licensing, knowledge transfer, or R&D collaborations to test and refine the technology in commercially relevant projects. In focus of a possible collaboration could be the development of a market-ready diagnostic assay, or the support of prospective studies with larger groups of patients.
Advantages and innovations
Reduced treatment time Reduced treatment costs Minimization of related side effects Personalization to patient
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below